-->

Tag: BTK inhibitor therapy

Home / BTK inhibitor therapy

Categories

Zanubrutinib is approved by the USFDA for relapsed or refractory follicular lymphoma

March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refra...
btk-inhibitor-therapy

Pirtobrutinib is approved by the USFDA for chronic lymphocytic leukemia and small lymphocytic lymphoma

The Food and Drug Administration granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) on December 1, 2023, for adults with chronic lymphocytic leukemia or small lymphocytic...
btk-inhibitor-therapy

Scan the code